Combination Rx/Device Products Should Have One FDA Filing, Wyeth Says
Executive Summary
Sponsors of combination drug/medical device products should not be required to submit two separate applications to FDA, Wyeth Associate Director-Regulatory Affairs Owen Fields, PhD, told an FDA public meeting on combination products Nov. 25
You may also be interested in...
FDA Office Of Combination Products To Clarify Review Assignment Process
FDA's Office of Combination Products plans to publish regulations or guidances to clarify the agency's mandate to assign review of combination products according to their primary mode of action
FDA Office Of Combination Products To Clarify Review Assignment Process
FDA's Office of Combination Products plans to publish regulations or guidances to clarify the agency's mandate to assign review of combination products according to their primary mode of action
Cell-Based Combos Should Go Through CBER For Non-Wound Uses – PhRMA
Cell-based combination therapies should be reviewed by the Center for Biologics Evaluation & Research for indications other than wound healing, Pharmaceutical Research & Manufacturers of America Biologics & Biotechnology/Preclinical Affairs Research Director Sara Radcliffe said June 24